Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 8/20 | 0.52 |
| ▸ | F2 | P00734 | 4/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8261183 | 1.00 | REN (0.55) | RENACEF2ACE2CTRB1 | |
| SCHEMBL13241217 | 1.00 | REN (0.55) | RENACEF2ACE2CTRB1 | |
| SCHEMBL22698803 | 1.00 | REN (0.55) | RENACEF2ACE2CTRB1 | |
| SCHEMBL8255495 | 1.00 | REN (0.55) | RENACEF2ACE2CTRB1 | |
| SCHEMBL2475863 | 1.00 | REN (0.55) | RENACEF2ACE2CTRB1 | |
| SCHEMBL8165627 | 1.00 | REN (0.55) | RENACEF2ACE2CTRB1 | |
| SCHEMBL8261170 | 1.00 | REN (0.55) | RENACEF2ACE2CTRB1 | |
| SCHEMBL8257154 | 0.96 | REN (0.52) | RENACEF2ACE2CTRB1 | |
| SCHEMBL30132290 | 0.94 | REN (0.54) | RENACEF2ACE2CTRB1 | |
| SCHEMBL13533688 | 0.92 | REN (0.55) | RENACEF2ACE2CTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250051830-A1 | MEMBRANE-EMBEDDED NANOPORE AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2025-02-13 | — | — | US | disclosed |
| US-12006329-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20230265153-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230212216-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | GENIE BIOTECH UK LTD. (GB) | 2023-07-06 | — | — | US | disclosed |
| WO-2023064805-A1 | MEMBRANE-EMBEDDED NANOPORE AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-11548928-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2023-01-10 | — | — | US | disclosed |
| US-11518796-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20070185060-A1 | Boronic acid thrombin inhibitors | TRIGEN LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| WO-2006059082-A1 | OXIDISED LIPIDS AS REVERSAL AGENTS FOR BORONIC ACID DRUGS | TRIGEN LIMITED (GB) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006059083-A1 | NEUTRALISING AGENTS FOR BORONIC ACID DRUGS | TRIGEN LIMITED (GB) | 2006-06-08 | — | — | WO | disclosed |
| US-20060084592-A1 | Peptide boronic acid inhibitors | TRIGEN LIMITED | 2006-04-20 | — | — | US | disclosed |
| US-20060084592-A1 | Peptide boronic acid inhibitors | TRIGEN LIMITED | 2006-04-20 | — | — | US | disclosed |
| US-20050282757-A1 | Peptide boronic acid compounds useful in anticoagulation | TRIGEN LIMITED | 2005-12-22 | — | — | US | disclosed |
| US-20050282757-A1 | Peptide boronic acid compounds useful in anticoagulation | TRIGEN LIMITED | 2005-12-22 | — | — | US | disclosed |
| WO-2005084686-A2 | BORONATE MEDICAMENTS FOR PREVENTING THROMBOSIS DURING SURGERY | TRIGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005084685-A2 | BORONATE MEDICAMENTS SUITABLE FOR SHORT DURATION ANTICOAGULATION | TRIGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005084687-A2 | BORONIC ACID THROMBIN INHIBITORS | TRIGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084592-A1 | Peptide boronic acid inhibitors | BMX, YBX1, HAX1 | REN 100/4885ACE 220/4885F2 2429/4885 |
| US-12006329-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | REN 1471/4885ACE 1053/4885F2 4092/4885 |
| US-20230212216-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | AGL, PGLS, DDOST | REN 4532/4885ACE 3445/4885F2 4638/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | REN 1471/4885ACE 1053/4885F2 4092/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | REN 1471/4885ACE 1053/4885F2 4092/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | REN 1471/4885ACE 1053/4885F2 4092/4885 |
| US-20050282757-A1 | Peptide boronic acid compounds useful in anticoagulation | SERPINC1, HABP2, F11 | REN 1916/4885ACE 1655/4885F2 6/4885 |
| US-20070185060-A1 | Boronic acid thrombin inhibitors | F2, ECE1, BCAT1 | REN 1635/4885ACE 230/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.